Compare ENTX & WAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | WAVE |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 47.5M |
| IPO Year | 2015 | 2021 |
| Metric | ENTX | WAVE |
|---|---|---|
| Price | $1.69 | $8.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 62.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | $436.84 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $4.52 |
| 52 Week High | $3.22 | $10.87 |
| Indicator | ENTX | WAVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 53.82 |
| Support Level | $1.45 | $6.99 |
| Resistance Level | $1.94 | $10.46 |
| Average True Range (ATR) | 0.28 | 0.85 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 30.87 | 46.32 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.